Inclusion Criteria:

- Women with known mutation of an HNPCC-associated gene (hMLH-1, hMSH-2, or hMSH-6) or
fulfill Amsterdam Criteria and have had one or more HNPCC-associated cancers

- No prior hysterectomy; (participants may be scheduled for prophylactic hysterectomy
following the study)

- Voluntary consent documented by a signed and witnessed informed consent

- Negative serum pregnancy test at baseline evaluation

- No history of pelvic irradiation for whatever cause

- No chemotherapy for two years

- Women >= 40 must have had a screening mammogram within the last 12 months prior to
participation in this study

- Women who are at 50% risk of having a mutation and willing to have genetic testing

Exclusion Criteria:

- Use of oral contraceptives or depoMPA or hormonal exposure, such as hormonal IUD,
tamoxifen, raloxifene, or other selective estrogen receptor modulators (SERMs) within
four months of initiating study; women will be asked to be off oral contraceptives or
other hormonal exposure for 4 months prior to initiating study

- Medical contraindication to use of oral contraceptives or depoMPA including:

- Known or suspected pregnancy

- Undiagnosed vaginal bleeding

- Known or suspected malignancy of breast or endometrium

- Active thrombophlebitis, or current or past history of thromboembolic disorders,
or cerebral vascular disease

- Gall bladder disease or liver dysfunction or disease, including hepatic adenomas
or carcinoma, or abnormal liver function tests

- Known hypersensitivity to depoMPA contraceptive injection (medroxyprogesterone
acetate or any of its other ingredients)

- Depression that is currently not under control, in the judgement of the
Principal Investigator

- History of epilepsy

- History of diabetes

- Coronary artery disease

- Age >=35 and a current tobacco smoker

- Known inability to participate in the scheduled follow-up tests (i.e., alcohol
dependence or illicit drug use)

- Significant medical history or psychiatric problems which would make the participant
a poor protocol candidate, in the opinion of the principal investigator

- Post surgical removal of both ovaries

- Postmenopausal women with amenorrhea greater than 12 months

- Previous history of endometrial biopsy, hysteroscopy, dilatation and curettage, or
IUD in place within the past 3 months

- Known participation in a concurrent protocol with a pharmacological intervention

- Recent or concurrent use of systemic steroids (i.e. prednisone) within the past four
months of initiating study

- Positive serum pregnancy test at baseline evaluation

- Fasting triglycerides level >= 400 mg/dl

- Cholesterol level >= 240 mg/dl

- LDL level >= 160 mg/dl

- HDL level =< 35 mg/dl

- Hypertension that is currently not under good control, in the judgement of the
principal investigator